DAPTOmycin

C. diff Risk

Low

Oral Bioavailability

NA

Approximate Cost

Non-formulary

Dosing

Adult

Endocarditis or bloodstream infection
6-10 mg/kg IV daily

Non-bloodstream infections
4 mg/kg IV daily

General Information

Common Usage

Targeted therapy of resistant gram positive infections with MRSA (particularly when MIC≥2) and VRE including endovascular infection

Drug Monitoring

Creatine kinase weekly

Adverse Effects

  • GI side effects common

  • Rash

  • Phlebitis

  • Increased INR

  • Myopathy including rhabdomyolysis

Major Interactions

Statins and fibrates - Increased myopathy. Monitor creatine kinase or hold while on daptomycin therapy.

Additional Information

Higher doses used for endovascular infection.

Recommend Infectious Disease Consult.

Inactivated by pulmonary surfactant and therefore insufficient for pulmonary infection.

Pharmacology

Antimicrobial class: Cyclic Lipopeptide.

Pregnancy category: B

Average serum half life: 9 hours

CSF penetration: Poor

Lung penetration: Poor

Urine penetration: Therapeutic